Journal of Shandong University (Health Sciences) ›› 2018, Vol. 56 ›› Issue (10): 3-8.doi: 10.6040/j.issn.1671-7554.0.2018.1028
CLC Number:
| [1] Collins Y, Holcomb K, Chapman-Davis E, et al. Gynecologic cancer disparities: a report from the Health Disparities Taskforce of the Society of Gynecologic Oncology[J]. Gynecol Oncol, 2014, 133(2): 353-361. [2] Bourla AB, Zamarin D. Immunotherapy: new strategies for the treatment of gynecologic malignancies[J]. Oncology(Williston Park), 2016, 30(1): 59-66, 69. [3] Su Z, Graybill WS, Zhu Y. Detection and monitoring of ovarian cancer[J]. Clin Chim Acta, 2013, 415: 341-345. doi: 10.1016/j.cca.2012.10.058. [4] 邹瑟音,夏勇,梁思宇,等. 联合检测肿瘤标志物在卵巢癌诊断中的临床应用评价[J].检验医学与临床, 2014, 11(23): 3316-3317. [5] 张宏兴. 血清CA125, CA199, CEA, AFP联监在卵巢癌诊断中应用价值研究[J].中国妇幼保健,2013, 25(3):4247-4249. ZHANG Hongxing. Study on application value of joint detection of serum CA125, CA19-9, CEA, and AFP in diagnosis of ovarian cancer [J]. Maternal and Child Health Care of China, 2013, 25(3): 4247-4249. [6] Rein BJ, Gupta S, Dada R, et al. Potential markers for detection and monitoring of ovarian cancer[J]. J Oncol, 2011, 2011: 475983. doi: 10.1155/2011/475983. [7] Buamah P. Benign conditions associated with raised serum CA-125 concentration[J]. J Surg Oncol, 2000, 75(4): 264-265. [8] Buamah PK, Skillen AW. Serum CA 125 concentrations in patients with benign ovarian tumours[J]. J Surg Oncol, 1994, 56(2): 71-74. [9] Niloff JM, Klug TL, Schaetzl E, et al. Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix[J]. Am J Obstet Gynecol, 1984, 148(8): 1057-1058. [10] Su Z, Graybill WS, Zhu Y. Detection and monitoring of ovarian cancer[J]. Clin Chim Acta, 2013, 415: 341-345. doi: 10.1016/j.cca.2012.10.058. [11] Tate S, Hirai Y, Takeshima N, et al. CA125 regression during neoadjuvant chemotherapy as an independent prognostic factor for survival in patients with advanced ovarian serous adenocarcinoma[J]. Gynecol Oncol, 2005, 96(1): 143-149. [12] Le T, Faught W, Hopkins L, et al. Importance of CA125 normalization during neoadjuvant chemotherapy followed by planned delayed surgical debulking in patients with epithelial ovarian cancer[J]. J Obstet Gynaecol Can, 2008, 30(8): 665-670. [13] Dupont J, Tanwar MK, Thaler HT, et al. Early detection and prognosis of ovarian cancer using serum YKL-40[J]. J Clin Oncol, 2004, 22(16): 3330-3339. [14] Santillan A, Garg R, Zahurak ML, et al. Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range[J]. J Clin Oncol, 2005, 23(36): 9338-9343. [15] Rustin GJ, Nelstrop AE, Mcclean P, et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125[J]. J Clin Oncol, 1996, 14(5): 1545-1551. [16] Kirchhoff C. Molecular characterization of epididymal proteins[J]. Rev Reprod, 1998, 3(2): 86-95. [17] Montagnana M, Danese E, Giudici S, et al. HE4 in ovarian cancer: from discovery to clinical application[J]. Adv Clin Chem, 2011, 55: 1-20. [18] Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass[J]. Gynecol Oncol, 2008, 108(2): 402-408. [19] Havrilesky LJ, Whitehead CM, Rubatt JM, et al. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence[J]. Gynecol Oncol, 2008, 110(3): 374-382. [20] Drapkin R, Von Horsten HH, Lin Y, et al. Human epididymis protein 4(HE4)is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas[J]. Cancer Res, 2005, 65(6): 2162-2169. [21] Azzam AZ, Hashad DI, Kamel NA. Evaluation of HE4 as an extrabiomarker to CA125 to improve detection of ovarian carcinoma: is it time for a step forward?[J]. Arch Gynecol Obstet, 2013, 288(1): 167-172. [22] Moore RG, Jabre-Raughley M, Brown AK, et al. Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass[J]. Am. J Obstet Gynecol, 2010, 203(3): 228.e1-228.e6. doi: 10.1016/j.ajog.2010.03.043. [23] Tian, Y, Wang C, Cheng L, et al. Determination of reference intervals of serum levels of human epididymis protein 4(HE4)in Chinese women [J] J Ovarian Res, 2015. 8(1): 72. [24] Kim JH, Skates SJ, Uede T, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer[J]. JAMA, 2002, 287(13): 1671-1679. [25] Yurkovetsky Z, Skates S, Lomakin A, et al. Development of a multimarker assay for early detection of ovarian cancer[J]. J Clin Oncol, 2010, 28(13): 2159-2166. [26] Pal MK, Rashid M, Bisht M. Multiplexed magnetic nanoparticle-antibody conjugates(MNPs-ABS)based prognostic detection of ovarian cancer biomarkers, CA-125, beta-2M and ApoA1 using fluorescence spectroscopy with comparison of surface plasmon resonance(SPR)analysis[J]. Biosens Bioelectron, 2015, 73: 146-152. doi: 10.1016/j.bios.2015.05.051. [27] Richardson MA. Complementary and alternative therapy use in gynecologic oncology: implications for clinical practice[J]. Gynecol Oncol, 2002, 84(3): 360-362. [28] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. [29] Du PL, Wu KS, Fang JY, et al. Cervical Cancer Mortality Trends in China, 1991-2013, and Predictions for the Future[J]. Asian Pac J Cancer Prev, 2015, 16(15): 6391-6396. [30] Ohara K, Tanaka Y, Tsunoda H, et al. Assessment of cervical cancer radioresponse by serum squamous cell carcinoma antigen and magnetic resonance imaging[J]. Obstet Gynecol, 2002, 100(4): 781-787. [31] Takeda M, Sakuragi N, Okamoto K, et al. Preoperative serum SCC, CA125, and CA19-9 levels and lymph node status in squamous cell carcinoma of the uterine cervix[J]. Acta Obstet Gynecol Scand, 2002, 81(5): 451-457. [32] Gaarenstroom KN, Kenter GG, Bonfrer JM, et al. Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis?[J]. Gynecol Oncol, 2000, 77(1): 164-170. [33] Chou CY, Wang ST, Kuo HC, et al. Serum level of squamous cell carcinoma antigen and tumor size are useful to identify preoperatively patients at high risk of cervical cancer[J]. Cancer, 1994, 74(9): 2497-2501. [34] Bolli JA, Doering DL, Bosscher JR, et al. Squamous cell carcinoma antigen: clinical utility in squamous cell carcinoma of the uterine cervix[J]. Gynecol Oncol, 1994, 55(2): 169-173. [35] Lo Gerfo P, Krupey J, Hansen HJ. Demonstration of an antigen common to several varieties of neoplasia[J]. N Engl J Med, 1971, 285(3): 138-141. [36] Borras G, Molina R, Xercavins J, et al. Tumor antigens CA 19.9, CA 125, and CEA in carcinoma of the uterine cervix[J]. Gynecol Oncol, 1995, 57(2): 205-211. [37] Kjaer SK, Van Den Brule AJ, Paull G, et al. Type specific persistence of high risk human papillomavirus(HPV)as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study[J]. BMJ, 2002, 325(7364): 572. [38] Castle PE, Solomon D, Schiffman M, et al. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities[J]. J Natl Cancer Inst, 2005, 97(14): 1066-1071. [39] Walker JL, Wang SS, Schiffman M, et al. Predicting absolute risk of CIN3 during post-colposcopic follow-up: results from the ASCUS-LSIL Triage Study(ALTS)[J]. Am J Obstet Gynecol, 2006, 195(2): 341-348. [40] 桑勇先. CA125的研究进展[J]. 中国医药指南,2013,11(12): 451-453. [41] Liu L, Xu X, Jia L, et al. Primary fallopian tube carcinoma-a retrospective analysis of 66 cases[J]. Eur J Gynaecol Oncol, 2015, 36(2): 161-167. [42] Kalampokas E, Sofoudis C, Boutas I, et al. Primary fallopian tube carcinoma: a case report and mini-review of the literature[J]. Eur J Gynaecol Oncol, 2014, 35(5): 595-596. [43] Duffy MJ, Bonfrer JM, Kulpa J, et al. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use[J].Int J Gynecol Cancer, 2005, 15(5): 679-691. [44] Levy T, Weiser R, Boaz M, et al. The significance of the pattern of serum CA125 level ascent to above the normal range in epithelial ovarian, primary peritoneal and tubal carcinoma patients[J]. Gynecol Oncol, 2013, 129(1): 165-168. [45] Papadimitriou CA, Markaki S, Lianos E, et al. Clinicopathological features of primary fallopian tube carcinoma: a single institution experience[J]. Eur J Gynaecol Oncol, 2009, 30(4): 389-395. [46] Rosen AC, Ausch C, Klein M, et al. p53 expression in fallopian tube carcinomas[J]. Cancer Lett, 2000, 156(1): 1-7. [47] Halon A, Rabczynski J. PCNA and laminin as prognostic factors in primary Fallopian tube carcinoma[J]. Folia Morphol, 2003, 62(4): 475-478. [48] Wang F, Sun GP, Zou YF, et al. Expression of COX-2 and Bcl-2 in primary fallopian tube carcinoma: correlations with clinicopathologic features[J]. Folia Histochem Cytobiol, 2011, 49(3): 389-397. [49] Chhabra S, Bhavani MandDeshpande A. Trends of vulvar cancer[J]. J Obstet Gynaecol, 2014, 34(2): 165-168. [50] Del Pino M, Rodriguez-Carunchio LandOrdi J. Pathways of vulvar intraepithelial neoplasia and squamous cell carcinoma[J]. Histopathology, 2013, 62(1): 161-175. |
| [1] | LI Bo-Bo, LI Dao-Tang, LIU Shu-Guang, WANG Xing-Wu. Expression of serum DKK-1 in esophageal cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2209, 47(6): 58-61. |
| [2] | CAO Dongyan, BI Xiaoning, SHEN Keng. Application of anti-Mullerian hormone in gynecologic oncology [J]. Journal of Shandong University (Health Sciences), 2018, 56(5): 8-12. |
| [3] | LI Xiaoying, LIU Fang, CHE Haijie, ZHANG Jinhui. Establishment and preliminary evaluation of a model for predicting the malignant probability of solitary pulmonary nodule with tumor markers [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(4): 60-64. |
| [4] | LUAN Li1, GUAN Shang-hui1, YANG Sheng-si1, CHENG Huan-huan2,4, WANG Na-na1, DONG Zhao-gang3,4, CHENG Yu-feng1. Application of WCX magnetic beads to serum proteome profiling in endometrial carcinoma [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2011, 49(5): 85-89. |
| [5] | JIANG Man1， GENG Ling-yun1， CAI Hong-fei1， WANG Ming-ming2， WANG Dong-fang1, WANG Jia-lin3， HAN Ming-yong1. Diagnostic model of lung cancer established with tumor markers and artificial neural network [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2010, 48(8): 88-. |
| [6] | SHANG Guan-Hong1，XIAO Wei1, DONG Liang1, LI Yu1, TIAN Hui2, ZHENG Tian-ying3. Clinical value of serum CYFRA 21-1, NSE and CEA in the diagnosis and prognosis of lung cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2010, 48(12): 134-137. |
| [7] | LI Bo-Bo, LI Dao-Tang, LIU Shu-Guang, WANG Xing-Wu. Expression of serum DKK-1 in esophageal cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2009, 47(6): 58-61. |
|
||
